Evolva Holding announced that Emergent BioSolutions has acquired Evolva’s anti-bacterial programme, the EV-035 series.
|Searching for more deal information? Current Partnering offers the following options:
The lead compound in the EV-035 series is the broad-spectrum antibiotic GC-072, which is being developed with US government biodefense funding.
For Evolva, this transaction is worth up to USD 70.5 million plus royalties.
Evolva will receive from Emergent an upfront payment of USD 1.5 million, an additional USD 4 million after the US government approves transfer of the GC-072 contract to Emergent, development milestone payments up to USD 65 million, and tiered royalties up to a maximum of 10% on product net sales generated from the EV-035 programme.
For further deal information visit Current Agreements (subscription required)
Scorecard: Top partnering deals by value in 2014
View: Top biotech companies
Report: Top 50 Big Biotech Partnering and M&A Deal Trends